Protocol of the SOCFC project: a longitudinal cohort study of ovarian cancer patients, high-risk populations, and healthy controls to identify factors and biomarkers associated with disease diagnosis and prognosis

被引:0
作者
Shi, Wenpei [1 ]
Zhang, Yue [2 ]
Cheng, Shanshan [2 ]
Zhao, Yaqian [2 ]
Li, Na [2 ]
Li, Yi [1 ]
Yang, Yingying [1 ]
Ding, Hui [2 ]
Li, Zhen [1 ]
Wang, Yu [2 ]
机构
[1] Tongji Univ, Shanghai Matern & Infant Hosp 1, Shanghai Inst Maternal Fetal Med & Gynecol Oncol, Sch Med,Clin Res Unit,Shanghai Key Lab Maternal Fe, Shanghai 200092, Peoples R China
[2] Tongji Univ, Shanghai Matern & Infant Hosp 1, Shanghai Inst Maternal Fetal Med & Gynecol Oncol, Sch Med,Dept Gynecol,Shanghai Key Lab Maternal Fet, Shanghai 200092, Peoples R China
基金
中国国家自然科学基金;
关键词
Ovarian cancer; High-risk; Cohort; Biobank; Longitudinal; MORTALITY; TRIAL;
D O I
10.1186/s12885-025-13652-9
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
BackgroundOvarian cancer (OC) poses a significant threat to women's health due to its insidious onset, tendency to metastasize, and high recurrence rate. These characteristics significantly impede early diagnosis and effective interventions. The current lack of effective screening and prognostic tools necessitates urgent solutions. The Shanghai Ovarian Cancer and Family Care Project (SOCFCP) is an ongoing cohort study aiming to address these challenges by identifying factors and biomarkers associated with OC onset, treatment, and prognosis. The ultimate goal is to develop predictive models and assessments crucial for diagnosing, treating, and prognosing the disease.MethodsDuring the study period from 2023 to 2028, the SOCFCP aims to recruit over 2000 patients with ovarian lesions, 900 high-risk individuals, and 3000 healthy controls in Shanghai, China, with long-term follow-up. The study comprises three cohorts: (1) a bidirectional patients cohort, comprising those diagnosed with ovarian disease and treated at the department of gynecologic oncology at Shanghai first maternity and infant hospital since 2013; (2) a prospective high-risk cohort, consisting of family members of ovarian and/or breast cancer patients, or individuals with related gene mutations; and (3) a healthy control cohort, drawn from women undergoing health examination at hospitals or participating in community gynecologic cancer screenings. Participants will attend regular visits for questionnaire surveys, anthropometric measurements, and the collection of biological specimens, such as blood, fecal, and tissue samples. Collected data encompass baseline information, sociodemographic details, hospital admission records, and biological and clinical parameters, alongside treatment information. Primary outcomes for the patient cohort include mortality, tumor recurrence, major complications, and changes in health-related quality of life post-diagnosis. For the high-risk and healthy cohorts, ovary-related diseases will serve as the primary outcome. Various predictive models, such as multivariate logistic models, Cox regression, and linear mixed-effects regression models, will be employed to analyze various endpoints appropriately.DiscussionThis extensive cohort study integrates a diverse range of information, including lifestyle factors, environmental influences, genetic characteristics, and clinical features, alongside an extensive collection of biological samples. The resources generated by this project will provide valuable foundations for a comprehensively understanding of the etiology, treatment, and prognosis of OC. The SOCFCP is poised to foster cutting-edge multidisciplinary research on OC, spanning both fundamental and clinical studies.Trial registrationNCT06118307 in ClinicalTrials.gov. Registration Date: November 7, 2023.
引用
收藏
页数:8
相关论文
共 25 条
[1]   Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries [J].
Bray, Freddie ;
Laversanne, Mathieu ;
Sung, Hyuna ;
Ferlay, Jacques ;
Siegel, Rebecca L. ;
Soerjomataram, Isabelle ;
Jemal, Ahmedin .
CA-A CANCER JOURNAL FOR CLINICIANS, 2024, 74 (03) :229-263
[2]   Effect of Screening on Ovarian Cancer Mortality The Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Randomized Controlled Trial [J].
Buys, Saundra S. ;
Partridge, Edward ;
Black, Amanda ;
Johnson, Christine C. ;
Lamerato, Lois ;
Isaacs, Claudine ;
Reding, Douglas J. ;
Greenlee, Robert T. ;
Yokochi, Lance A. ;
Kessel, Bruce ;
Crawford, E. David ;
Church, Timothy R. ;
Andriole, Gerald L. ;
Weissfeld, Joel L. ;
Fouad, Mona N. ;
Chia, David ;
O'Brien, Barbara ;
Ragard, Lawrence R. ;
Clapp, Jonathan D. ;
Rathmell, Joshua M. ;
Riley, Thomas L. ;
Hartge, Patricia ;
Pinsky, Paul F. ;
Zhu, Claire S. ;
Izmirlian, Grant ;
Kramer, Barnett S. ;
Miller, Anthony B. ;
Xu, Jian-Lun ;
Prorok, Philip C. ;
Gohagan, John K. ;
Berg, Christine D. .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2011, 305 (22) :2295-2303
[3]   CA125 and Ovarian Cancer: A Comprehensive Review [J].
Charkhchi, Parsa ;
Cybulski, Cezary ;
Gronwald, Jacek ;
Wong, Fabian Oliver ;
Narod, Steven A. ;
Akbari, Mohammad R. .
CANCERS, 2020, 12 (12) :1-29
[4]  
Chinese expert consensus on clinical diagnosis and treatment of familial hereditary tumors, 2021, Chinese Journal of Clinical Oncology, V48, P1243
[5]   Ovarian Cancer [J].
Cho, Kathleen R. ;
Shih, Ie-Ming .
ANNUAL REVIEW OF PATHOLOGY-MECHANISMS OF DISEASE, 2009, 4 :287-313
[6]   Genetic/Familial High-Risk Assessment: Breast, Ovarian, and Pancreatic, Version 2.2024 Featured Updates to the NCCN Guidelines [J].
Daly, Mary B. ;
Pal, Tuya ;
Maxwell, Kara N. ;
Churpek, Jane ;
Kohlmann, Wendy ;
Alhilli, Zahraa ;
Arun, Banu ;
Buys, Saundra S. ;
Cheng, Heather ;
Domchek, Susan M. ;
Friedman, Susan ;
Giri, Veda ;
Goggins, Michael ;
Hagemann, Andrea ;
Hendrix, Ashley ;
Hutton, Mollie L. ;
Karlan, Beth Y. ;
Kassem, Nawal ;
Khan, Seema ;
Khoury, Katia ;
Kurian, Allison W. ;
Laronga, Christine ;
Mak, Julie S. ;
Mansour, John ;
McDonnell, Kevin ;
Menendez, Carolyn S. ;
Merajver, Sofia D. ;
Norquist, Barbara S. ;
Offit, Kenneth ;
Rash, Dominique ;
Reiser, Gwen ;
Senter-Jamieson, Leigha ;
Shannon, Kristen Mahoney ;
Visvanathan, Kala ;
Welborn, Jeanna ;
Wick, Myra J. ;
Wood, Marie ;
Yurgelun, Matthew B. ;
Dwyer, Mary A. ;
Darlow, Susan D. .
JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK, 2023, 21 (10) :1000-1010
[7]   Real-world evidence in the treatment of ovarian cancer [J].
Eisenhauer, E. A. .
ANNALS OF ONCOLOGY, 2017, 28 :61-65
[8]   A Follow-Up Study of Ovarian Cancer (OOPS): A Study Protocol [J].
Gong, Ting-Ting ;
Liu, Fang-Hua ;
Liu, Ya-Shu ;
Yan, Shi ;
Xu, He-Li ;
He, Xin-Hui ;
Wei, Yi-Fan ;
Qin, Xue ;
Gao, Song ;
Zhao, Yu-Hong ;
Wu, Qi-Jun .
FRONTIERS IN NUTRITION, 2022, 9
[9]   Using Big Data to Emulate a Target Trial When a Randomized Trial Is Not Available [J].
Hernan, Miguel A. ;
Robins, James M. .
AMERICAN JOURNAL OF EPIDEMIOLOGY, 2016, 183 (08) :758-764
[10]   Ovarian cancer screening and mortality in the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS): a randomised controlled trial [J].
Jacobs, Ian J. ;
Menon, Usha ;
Ryan, Andy ;
Gentry-Maharaj, Aleksandra ;
Burnell, Matthew ;
Kalsi, Jatinderpal K. ;
Amso, Nazar N. ;
Apostolidou, Sophia ;
Benjamin, Elizabeth ;
Cruickshank, Derek ;
Crump, Danielle N. ;
Davies, Susan K. ;
Dawnay, Anne ;
Dobbs, Stephen ;
Fletcher, Gwendolen ;
Ford, Jeremy ;
Godfrey, Keith ;
Gunu, Richard ;
Habib, Mariam ;
Hallett, Rachel ;
Herod, Jonathan ;
Jenkins, Howard ;
Karpinskyj, Chloe ;
Leeson, Simon ;
Lewis, Sara J. ;
Liston, William R. ;
Lopes, Alberto ;
Mould, Tim ;
Murdoch, John ;
Oram, David ;
Rabideau, Dustin J. ;
Reynolds, Karina ;
Scott, Ian ;
Seif, Mourad W. ;
Sharma, Aarti ;
Singh, Naveena ;
Taylor, Julie ;
Warburton, Fiona ;
Widschwendter, Martin ;
Williamson, Karin ;
Woolas, Robert ;
Fallowfield, Lesley ;
McGuire, Alistair J. ;
Campbell, Stuart ;
Parmar, Mahesh ;
Skates, Steven J. .
LANCET, 2016, 387 (10022) :945-956